Isis Pharmaceuticals said this week that it has teamed with Biogen Idec to develop antisense-based drugs for neurological and neuromuscular disorders.
Isis will receive an upfront payment of $30 million, and is responsible for discovering a lead antisense drug for three undisclosed targets. Isis will be responsible for developing the drugs through phase II testing, and Biogen Idec will have the option to license the compounds until this point.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.